The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules
Open accessAbstract
Purpose Subregional hypoxia is a common feature of tumors and is recognized as a limiting factor for the success of radiotherapy and chemotherapy. TH-302, a hypoxia-activated prodrug selectively targeting hypoxic regions of solid tumors, delivers a cytotoxic warhead to the tumor, while maintaining relatively low systemic toxicity. The antitumor activity, different dosing sequences, and dosing regimens of TH-302 in combination with commonly used conventional chemotherapeutics were investigated in human tumor xenograft models.Methods Seven chemotherapeutic drugs (docetaxel, cisplatin, pemetrexed, irinotecan, doxorubicin, gemcitabine, and temozolomide) were tested in combination with TH-302 in eleven human xenograft models, including non-small cell lung cancer (NSCLC), colon cancer, prostate cancer, fibrosarcoma, melanoma, and pancreatic cancer.Results The antitumor activity of docetaxel, cisplatin, pemetrexed, irinotecan, doxorubicin, gemcitabine, and temozolomide was increased when combined with TH-302 in nine out of eleven models tested. Administration of TH-302 2-8 h prior to the other chemotherapeutics yielded superior efficacy versus other sequences tested. Simultaneous administration of TH-302 and chemotherapeutics increased toxicity versus schedules with dosing separations. In a dosing optimization study, TH-302 administered daily at 50 mg/kg intraperitoneally for 5 days per week in the H460 NSCLC model showed the optimal response with minimal toxicity.Conclusions TH-302 enhances the activity of a wide range of conventional anti-neoplastic agents in a broad panel of in vivo xenograft models. These data highlight in vivo effects of schedule and order of drug administration in regimen efficacy and toxicity and have relevance to the design of human regimens incorporating TH-302.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“the HAP evofosfamide (also known as TH-302) was reported to enhance the anticancer activity of chemotherapy drugs in mouse xenograft models of various cancer types, including CRC [216].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [216]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828 · cited 1×
“Major reasons for hypoxic tumor tissue resistance to chemotherapy include their distance from blood vessels and slower rate of proliferation [4, 26].”
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805 · cited 1×
“Doxorubicin is a poor tissue penetrator, and multiple previous studies have documented its inability to reach the hypoxic tumor compartment efficiently [28, 31].”
Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects
Hockel, M., & Vaupel, P. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.4.266 · Cited by 2,662 · cited 1×
“Hypoxic regions are common in tumors and contribute to malignant progression, metastasis and often resistance to both chemotherapy and radiotherapy [12, 43].”
Hypoxia in cancer: significance and impact on clinical outcome
Vaupel, P., & Mayer, A. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9055-1 · Cited by 2,240 · cited 1×
“The magnitude of tumor hypoxia measured in patients’ tumor tissue correlates with reduced survival [40].”
Hypoxia-Inducible Factors, Stem Cells, and Cancer
Keith, B., & Simon, M. C. (2007) · Cell · doi:10.1016/j.cell.2007.04.019 · Cited by 1,179
Repopulation of cancer cells during therapy: an important cause of treatment failure
Kim, J. J., & Tannock, I. F. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1650 · Cited by 686 · cited 1×
“The faster tumor regrowth kinetics that we observed with doxorubicin, cisplatin, irinotecan, and gemcitabine may be due to the selective sparing of stem cells in the hypoxic regions of xenografts [22, 39].”
Teicher, B. A., Lazo, J. S., & Sartorelli, A. C. (1981) · PubMed · Cited by 555
The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors
Primeau, A. J., Rendon, A., Hedley, D., Lilge, L., & Tannock, I. F. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1664 · Cited by 499 · cited 2×
“, doxorubicin and mitoxantrone [31, 38]; others exhibit low activity on slowly proliferating cells, e.”
Rischin, D., Peters, L. J., O'Sullivan, B., Giralt, J., Fisher, R., Yuen, K., Trotti, A., Bernier, J., Bourhis, J., Ringash, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4449 · Cited by 380 · cited 1×
“Hypoxia-activated compounds that have progressed to clinical trials for the treatment of cancer include tirapazamine [32], AQ4N [29], PR-104 [17], and TH-302 [41].”
Cited by
Mimeault, M., & Batra, S. K. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12004 · Cited by 330
“For instance, it has been observed that a hypoxia-activated pro-drug designated as TH-302, which selectively targets hypoxic regions of solid tumours in combination with conventional chemotherapeutic drugs such as gemcitabine-induced greater anti-tumoral effects on diverse human tumour xenograft models including pancr…”
BackgroundMejia Oneto, J. M., Khan, I., Seebald, L., & Royzen, M. (2016) · ACS Central Science · doi:10.1021/acscentsci.6b00150 · Cited by 215
Mechanisms of Taxane Resistance
Maloney, S., Spring, C., Morejon-Lasso, L., & Prosperi, J. (2020) · Cancers · doi:10.3390/cancers12113323 · Cited by 198
“TH-302, a hypoxia-induced pro-drug (HAP), functions as a DNA alkylating agent to induce damage and cell death [450].”
BackgroundBorad, M. J., Reddy, S. G., Bahary, N., Uronis, H. E., Sigal, D., Cohn, A. L., Schelman, W. R., Stephenson, J., Chiorean, E. G., Rosen, P. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.7504 · Cited by 197
Interfering with Tumor Hypoxia for Radiotherapy Optimization
Telarovic, I., Wenger, R. H., & Pruschy, M. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02000-x · Cited by 185
Metadata
- Authors
- Liu, Q., Sun, J. D., Wang, J., Ahluwalia, D., Baker, A. F., Cranmer, L. D., Ferraro, D., Wang, Y., Duan, J.-X., Ammons, W. S., Curd, J. G., Matteucci, M. D., & Hart, C. P.
- Affiliations
- Threshold Pharmaceuticals (United States) (US)
- University of Arizona (US)
- Corresponding author
- Hart, Charles P.
- ORCID
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 2012-03-02
- Volume
- 69
- Issue
- 6
- Pages
- 1487-1498
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- PMC
- PMC3985381
- OpenAlex
- W2087565365
- Cited by
- 113
- References
- 45
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 6 · 2023: 3 · 2022: 3 · 2021: 7 · 2020: 8 · 2019: 8 · 2018: 8 · 2017: 8 · 2016: 17 · 2015: 15 · 2014: 9 · 2013: 13 · 2012: 2
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Chemotherapy and Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P50 CA95060, R01CA125627, P50CA095060, P30CA023074)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
- Keywords
- TH-302, hypoxia-activated prodrug, tumor hypoxia, combination chemotherapy, dosing regimen, dosing regimen optimization, chemotherapy toxicity, non-small cell lung cancer, xenograft models, docetaxel, cisplatin, pemetrexed, irinotecan, doxorubicin, gemcitabine, temozolomide
- MeSH terms
- Pemetrexed, Docetaxel, Irinotecan, Gemcitabine, Animals, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Cisplatin, Deoxycytidine, Drug Evaluation, Preclinical, Glutamates, Guanine, Humans, Nitroimidazoles, Phosphoramide Mustards, Prodrugs, Cell Hypoxia, Mice, SCID, Xenograft Model Antitumor Assays, Taxoids, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules. https://app.cochat.ai/papers/10.1007/s00280-012-1852-8
- The paper
- Liu, Q., Sun, J. D., Wang, J., Ahluwalia, D., Baker, A. F., Cranmer, L. D., Ferraro, D., Wang, Y., Duan, J.-X., Ammons, W. S., Curd, J. G., Matteucci, M. D., & Hart, C. P. (2012). TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-012-1852-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.